# GLP-1 weight-loss drug market regulation in Africa

> Live situation record from CLSTR: https://clstr.news/situations/glp-1-weight-loss-drug-market-regulation-in-africa
> Updated: 2026-10-14T15:49:00.000Z. Sources: 5. Developments: 2.

The market for GLP-1 weight-loss medications is expanding significantly across Africa, with South Africa serving as a primary hub. While the market has reached substantial valuations, the surge in demand has led to increased regulatory scrutiny and the emergence of illicit trade.

Regulators, including the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC), have taken action against unauthorized compounding practices to prevent the manufacturing of counterfeit medicines. Concerns have been raised regarding a growing black market where unregistered drugs, such as the experimental retatrutide, are sold through informal channels like social media and gym instructors.

In response to high costs and regulatory crackdowns, new service models have emerged. The health management programme Obiflex introduced a ‘buy now, pay later’ option, providing virtual consultations and interest-free installments to help patients access legitimate medication while avoiding unregulated alternatives.

## Claims

- Aspen reported that the local GLP-1 market in South Africa nearly doubled to approximately 170 million USD for the fiscal year ending June 2026. (single source)
- Novo Nordisk launched Ozempic and Wegovy in Kenya in September 2026. (single source)
- The South African Pharmacy Council and SAHPRA are developing updated standards and guidelines for compounding medicines. (single source)
- The South African Pharmacy Council expressed concern regarding pharmacies acting as small-scale manufacturers through large-scale compounding. (single source)
- The experimental obesity drug retatrutide is being sold openly in South Africa despite not being approved by any regulator. (single source)
- The Pharmaceutical Task Group has called for law enforcement action against the sale of unregistered medicines. (single source)

## Timeline

### 2026-10-14: South Africa regulates weight-loss drug compounding amid rising black market

South Africa is tightening regulations on compounded weight-loss drugs as the GLP-1 market grows and illegal, unregistered medicines are sold through informal channels and social media.

3 sources. https://clstr.news/cluster/south-africa-regulates-weight-loss-drug-compounding-amid-rising-black-market

### 2026-09-29: Obiflex introduces installment payments for GLP-1 weight-loss drugs in South Africa

Obiflex has launched a ‘buy now, pay later’ service in South Africa to help patients afford GLP-1 weight-loss medications, aiming to provide a legitimate alternative to unregulated illicit drugs.

2 sources. https://clstr.news/cluster/obiflex-introduces-installment-payments-for-glp-1-weight-loss-drugs-in-south-africa

---
Cite as: GLP-1 weight-loss drug market regulation in Africa. CLSTR, https://clstr.news/situations/glp-1-weight-loss-drug-market-regulation-in-africa